Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Endpoint:
mechanistic studies
Type of information:
experimental study
Adequacy of study:
key study
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: scientifically acceptable publication

Data source

Reference
Reference Type:
publication
Title:
Quantitation of Alpha2u-Globulin in Rat Kidney Cytosol by Capillary Electrophoresis
Author:
Pähler A, Blumbach K, Herbst J, and Dekant W
Year:
1999
Bibliographic source:
Analytical Biochemistry 267: 203–211

Materials and methods

Principles of method if other than guideline:
Alpha2u-globulin in renal enal cytosol fractions was analyzed by capillary electrophoresis as protein–SDS complexes after treatment with test substance.
GLP compliance:
no
Remarks:
welldocumented publication
Type of method:
in vivo
Endpoint addressed:
carcinogenicity

Test material

Constituent 1
Reference substance name:
Kaolin
Cas Number:
1332-58-7
IUPAC Name:
Kaolin
Details on test material:
- Name of test material (as cited in study report): dimethyl methylphosphonate (DMMP) obtained from Aldrich Chemical Company (Deisenhofen, Germany)
No additional details provided; all chemicals used were reagent, electrophoresis, or gradient grade as commercially available.

Test animals

Species:
rat
Strain:
Fischer 344
Sex:
male
Details on test animals or test system and environmental conditions:
TEST ANIMALS
- Source: Fischer F344/N rats were obtained from Harlan Winkelmann (Borchen, FRG)
- Age at study initiation: adult animals were used
- Acclimation period: 3 days (before the experiments, the animals were accustomed to the metabolic cages for 3 days and control urine was collected for 12 h before the exposures.)

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21°C
- Photoperiod (hrs dark / hrs light): 12-h light/dark cycle

No additional data provided

Administration / exposure

Route of administration:
oral: gavage
Vehicle:
corn oil
Details on exposure:
PREPARATION OF DOSING SOLUTIONS:
No details data provided
Analytical verification of doses or concentrations:
no
Duration of treatment / exposure:
5 days
Frequency of treatment:
once daily
Post exposure period:
At the end of treatment, animals were sacrificed by cervical dislocation and kidney cytosolic subcellular fractions were prepared.
Doses / concentrations
Remarks:
Doses / Concentrations:
0, 500 and 1000 mg/kg bw per day
Basis:
actual ingested
No. of animals per sex per dose:
5
Control animals:
yes, concurrent vehicle
Details on study design:
no further details provided

Examinations

Examinations:
Rat kidney cytosolic subcellular fractions of treated rats were prepared and protein concentrations in liquid samples determined. The protein separation was then performed with an anion-exchange column and a high-performance liquid chromatography system. The eluent representing a2u-globulin was collected, pooled, desalted by gel filtration chromatography, lyophilized, and stored at 280°C.
Renal cytosol fractions were analyzed by capillary electrophoresis as protein–SDS complexes. Using a2u-globulin purified from urine of male rats, the limit of detection was 10 mg/ml sample in routine analyses. Excellent run to run reproducibility in migration time (CV≤4%) and peak areas corresponding to a2u-globulin (CV≤3%) after normalization to the internal standard was observed.
Positive control:
The test substance was evaluated together with 4 other compounds, some of which also showed a positive response

Results and discussion

Details on results:
Significant increases in renal alpha2u-globulin content (up to 85% of total protein content) compared to controls (approx 15%) were observed in kidney cytosol of rats treated with alpha2u-globulin nephropathy-inducing agents such as trimethylpentane or the alkylphosphonates dimethyl methylphosphonate and diethyl ethylphosphonate, but not in kidney cytosol of male rats treated with tris-(2- chloroethyl)phosphate or the nephrotoxic agent hexachlorobutadiene (see Tables 1&2). A good correlation of the alpha2u-globulin contents determined by capillary electrophoresis and immunoblotting with an a2u-globulin-specific antibody (r2=0.997) was obtained. Capillary electrophoresis provides a simple, rapid, and highly reproducible quantitation of a2u-globulin accumulation for renal tumorigens and may assist in the risk assessment process for these chemicals.

Any other information on results incl. tables

Table 1: Alpha2u-Globulin Content (Determined by Capillary Electrophoresis) in Kidney Cytosol of Male Rats Treated with Several Nephrotoxic Compounds(a)

Treatment

Alpha2u-Globulin Content

(% of total protein)

CV(%)

(= SD/mean*100)

Untreated control

14.7 ± 4.8

32

TCEP, 250 mg/kg

19.4 ± 6.1

31

HCBD, 200 mg/kg

9.1 ± 7.5

82

DMMP, 500 mg/kg

68.9 ± 3.4

5

DMMP, 1000 mg/kg

78.4 ± 5.1

7

DEEP, 50 mg/kg

56.4 ± 8.3

15

DEEP, 100 mg/kg

62.4 ± 4.2

7

TMP, 50 mg/kg

85.2 ± 7.0

8

Note: data are shown as means ± SD and show interanimal variation; (a) n = 5 animals per treatment group, samples of individual animals were run as triplicates

 

Table 2: Comparison of the Intraassay Variation in Determined alpha2u-Globulin Content in Individual Kidney Cytosol Samples from Untreated Male Rats and Male Rats Treated with alpha2u-Globulin-Inducing Agents by Western Blot Analysis with an alpha2u-Globulin-Specific Antibody or by Capillary Electrophoresis

Treatment

alpha2u-Globulin Conte

Western blot/specific

antibody (intensity

relative to control)

CV(%)

(SD/mean*100)

CE-SDS (% of total

cytosolic protein)

CV(%)

(SD/mean*100)

Untreated control

1.0 ± 0.1

14

15.3 ± 0.5

3

TCEP, 250 mg/kg

1.4 ± 0.4

31

17.5 ± 1.1

6

HCBD, 200 mg/kg

0.9 ± 0.2

23

10.2 ± 0.7

7

DMMP, 500 mg/kg

4.5 ± 0.7

16

69.5 ± 0.5

1

DMMP, 1000 mg/kg

5.4 ± 1.1

22

79.8 ± 2.6

3

DEEP, 50 mg/kg

3.6 ± 0.6

16

53.3 ± 4.1

8

DEEP, 100 mg/kg

4.4 ± 0.7

17

65.2 ± 1.0

2

TMP, 50 mg/kg

4.8 ± 1.0

20

81.0 ± 4.7

6

Note: data are means ± SD, n = 3, and were determined in three samples from one animal per treatment group

 

Applicant's summary and conclusion